Reports preliminary FY25 revenue $380M, consensus $374M. “We had another quarter of strong testing services volume growth and record revenue across all segments of our business,” said John Hanna, president and CEO. “Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- NeoGenomics CFO Jeff Sherman to retire, Abhishek Jain to succeed
- Craig-Hallum downgrades CareDx to Hold on less compelling risk-reward
- CareDx downgraded to Hold from Buy at Craig-Hallum
- CareDx Wins Preliminary Court Approval for Derivative Settlement
- CareDx price target raised to $18 from $14 at Wells Fargo